Testing Af-001, an alpha-particle radiopharmaceutical, in people with differentiated thyroid cancer
Tests Af-001 in adults with differentiated thyroid cancer that has spread or returned.
Plain-language title generated from the registry record
Registry title: A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer
Key facts
- Where
- Kashiwa, JapanSee the site
- Phase
- Phase 1
Where in Japan
- National Cancer Center Hospital EastKashiwa, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alpha Fusion Inc.
- Trial code
- NCT07287748
- Record updated
- 31 December 2025
- Original description
This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) refractory to or intolerant of standard-of-care therapy, who have received total thyroidectomy, and to determine the MTD (Maximum tolerated dose).Read full original descriptionShow less
A Phase I Trial of the Alpha Particle-emitting Radiopharmaceutical, Af-001, in Patients With Differentiated Thyroid Cancer
This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) refractory to or intolerant of standard-of-care therapy, who have received total thyroidectomy, and to determine the MTD (Maximum tolerated dose).
Part Ib is to evaluate the efficacy and safety of af-001 mutiple doses to patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma), who have received total thyroidectomy and are RAI naïve, randomized into two arms at the determined MTD or the MTD-1 dose level, and to determine the recommended Phase II dose (RP2D)
Inclusion: <Ia part>; Patients with differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) after total thyroidectomy; Patients with radically unresectable, recurrent, metastatic disease who are judged by the principal investigator or sub-investigator (hereinafter, "principal/sub-investigators") to be refractory to or intolerant of standard-of-care therapy; <Ib part>; Patients with radically unresectable, recurrent, metastatic disease who are RAI naive; Patients with measurable lesions. <Ia/Ib part>; Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 and stable general condition; Patients expected to survive for at least 6 additional months based on clinical symptoms and physical examination findings.
Exclusion: Patients with uncontrolled active infections; Patients who are positive for hepatitis B virus surface (HBs) antigen, hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) antibodies; Patients with active multiple cancers (synchronous multiple cancers and ectopic double cancers with a disease-free period of <=3 years); <Ia/Ib part>; Patients who need to preserve fertility; Females who are pregnant or may be pregnant, breastfeeding patients, or patients or their partners who cannot agree to appropriate contraception.